Provention Bio Inc. (PRVB) Announces Proposed 5.5M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
Provention Bio Inc. (PRVB) Prices 6.6M Share Common Offering at $14.50/Sh
June 18, 2020 5:58 AM EDTProvention Bio, Inc., (NASDAQ: PRVB) today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share. Gross proceeds to Provention Bio from the offering are expected to be $95.7 million, before deducting underwriting discounts... More
Provention Bio Inc. (PRVB) PT Raised to $26 at H.C. Wainwright
June 16, 2020 6:34 AM EDTH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Provention Bio Inc. (NASDAQ: PRVB) to $26.00 (from $20.00) while maintaining a Buy rating.... More
Provention Bio Inc. (PRVB) Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
June 15, 2020 12:09 PM EDTProvention Bio, Inc. (Nasdaq: PRVB) announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly delayed the onset of insulin-dependent type 1 diabetes (T1D) in presymptomatic patients by a median of approximately three years compared to placebo. These new data from the pivotal "At-Risk" TN-10 Study add one year to the two-year median delay that was previously reported in the New England Journal of Medicine and presented at last year's American Diabetes Association's (ADA's) Scientific Sessions. Teplizumab, Provention's lead drug candidate, is an anti-CD3 monoclonal antibody in development for the... More
Provention Bio Inc. (PRVB) gains on talk of positive diabetes data
June 15, 2020 11:31 AM EDTProvention Bio Inc. (NASDAQ: PRVB) gains on talk of positive diabetes data.
... More